
- Affiliated company
- Former PRIMA Project Leader (2013 - 2020)Pixium Vision
Martin Deterre is a graduate of Polytechnique and MIT with a PhD and 13 years of experience in MedTech innovation. Currently, he is the CEO of Theraclion, a publicly traded startup developing and commercializing breakthrough robotic therapeutic ultrasound (HIFU) devices aimed at revolutionizing surgery with non-invasive robotic procedures. Theraclion's products are on the market for varicose veins, thyroid nodules, and breast fibroadenoma treatments, generating multi-million euros in annual revenues with strong ambitions in the US, Chinese, and EU markets. Deterre successfully led an R&D team to bring an artificial vision, retinal implantan implanted electronic device that stimulates surviving retinal neurons to create visual percepts device from academic research to FDAthe U.S. federal agency that regulates medical devices, drugs, biological products, and other health-related products and EU clinical triala research study in people that evaluates a medical intervention approval in four years, enabling blindsevere vision loss that may still include some remaining sight patients to read words again and advancing the project to pivotal clinical study. He is known for his execution and delivery orientation, field/customer/patient-driven approach, creative thinking, and leadership in fast-paced startup environments.
Experience
Education
IEF, Univ. Paris-Sud, Orsay, FrancePhD, Micro & Nano Systems2010 - 2013
Article information
How verification worksNot yet verified. This page has not been verified by an expert yet, so the information presented here may be incomplete or inaccurate.
Last updated May 16, 2024 at 12:19 PM.
The following people contributed to this page:
- Michael BeyelerAssociate Professor, UC Santa Barbara

